文章基本信息

标题：Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective
本地全文：下载
作者：Werner A Scherbaum ; Gordon Goodall ; Katrina M Erny-Albrecht 等
期刊名称：Cost Effectiveness and Resource Allocation
印刷版ISSN：1478-7547
电子版ISSN：1478-7547
出版年度：2009
卷号：7
期号：1
页码：9
DOI：10.1186/1478-7547-7-9
语种：English
出版社：BioMed Central
摘要：The aim of this study was to project health-economic outcomes relevant to the German setting for the addition of pioglitazone to existing treatment regimens in patients with type 2 diabetes, evidence of macrovascular disease and at high risk of cardiovascular events. Event rates corresponding to macrovascular outcomes from the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) study of pioglitazone were used with a modified version of the CORE Diabetes Model to simulate outcomes over a 35-year time horizon. Direct medical costs were accounted from a healthcare payer perspective in year 2005 values. Germany specific costs were applied for patient treatment, hospitalization and management. Both costs and clinical benefits were discounted at 5.0% per annum. Over patient lifetimes pioglitazone treatment improved undiscounted life expectancy by 0.406 years and improved quality-adjusted life expectancy by 0.120 quality-adjusted life years (QALYs) compared to placebo. Direct medical costs (treatment plus complication costs) were marginally higher for pioglitazone treatment and calculation of the incremental cost-effectiveness ratio (ICER) produced a value of €13,294 per QALY gained with the pioglitazone regimen versus placebo. Acceptability curve analysis showed that there was a 78.2% likelihood that pioglitazone would be considered cost-effective in Germany, using a
关键词：Pioglitazone ; Glycaemic Control ; United Kingdom Prospective Diabetes Study ; Macrovascular Event ; Pioglitazone Treatment